Showing 4671-4680 of 8849 results for "".
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infectionshttps://practicaldermatology.com/news/la-biomed-team-to-study-treatments-for-antibiotic-resistant-skin-infections/2457533/Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study,
- Almirall, LLC is the New Name of Aquahttps://practicaldermatology.com/news/aqua-is-now-almirall/2457551/Almirall, LLC is the new name of Aqua Pharmaceuticals. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, with a strong focus on skin health. The name change, was announced jointly by Almirall LLC Pre
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder
- New from Lumenis: NuEra Tight Radio Frequency Devicehttps://practicaldermatology.com/news/new-from-lumenis-nuera-tight-radio-frequency-device/2457558/Lumenis has launched NuEra tight, a non-invasive, intelligent temperature-controlled technology for both superficial and deep heating that treats a variety of conditions, such as skin laxi
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta
- ISDIN Launches Melatonik Nighttime Serumhttps://practicaldermatology.com/news/isdin-launches-melatonik-nighttime-serum/2457577/ISDIN's Melatonik nighttime serum formulated with melatonin, bakuchiol (a natural antioxidant with retinol-like properties) and Vitamin C, is now available. It was developed to help skin recover from the day and prepare it to fi
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- What Happens When "Award Winning Hair Transplant Surgeons Meet"?https://practicaldermatology.com/news/what-happens-when-award-winning-hair-transplant-surgeons-meet/2457587/Boasting "true star power" with a lineup of international speakers and educational offerings in the ever-expanding field of hair transplant surgery, the 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) heads to Hollywood October 10-14.&